Hospitals do not prescribe more expensive drugs because they know the 340B program will help pay for them.
That is the conclusion drawn in a recent analysis by the Medicare Payment Advisory Commission.
Prescription drug spending has risen markedly in recent years and the pharmaceutical industry maintains that part of that increase can be attributed to hospitals that participate in the section 340B prescription drug discount program, which requires pharmaceutical companies to give discounts to hospitals and other selected providers that care for especially large numbers of low-income patients.
A new analysis by the Medicare Payment Advisory Commission, however, concludes that any such effect is minimal.
340B discounts are available for qualified patients receiving drugs on an outpatient basis, and the program’s greatest costs are associated with drugs to treat cancer. MedPAC found that prescribing decisions “appears to be specific to the type of cancer” and concluded that “…we are unable to attribute these findings to incentives created by 340B discounts” and that “Overall effects on cost sharing for cancer patients is likely to be small, if any, depending on cancer and the patient’s supplemental coverage.”
MedPAC warns that the empirical evidence underlying its analysis was limited.
Most private safety-net hospitals participate in the 340B program and consider it a vital resource in helping them serve their many low-income patients.
Learn more about the impact of the 340B program on the drugs prescribed by participating hospitals in the Becker’s Hospital Review article “340B has minimal effect on health spending, study finds” and the MedPAC presentation “Congressional request on health care provider consolidation: Does the 340B program create incentives for participating hospitals to use more expensive drugs?”